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South Africa (SA) has the largest HIV epidemic in the world; therefore, 
it is critical to expand HIV testing services and early initiation 
of antiretroviral treatment to reduce AIDS mortality and onward 
transmission.[1] Too few South Africans know their HIV status, with 
a large proportion of people living with HIV undiagnosed.[2] In SA, 
despite great progress towards the Joint United Nations Programme on 
HIV and AIDS (UNAIDS) 90-90-90 targets, which were 85%-71%-87% 
in 2017, the HIV prevalence remains high in certain provinces, e.g. 
Mpumalanga Province, SA, with an increase of 14 - 17.3% in 2012 
- 2017.[2,3] The National Department of Health devised strategies to 
expand the HIV testing service (HTS), but poor uptake of testing and 
failure to link to and remain in care persist, leading to late diagnosis 
and increased morbidity and mortality.[3] The failure to test and link to 
care is more pronounced among men who have sex with men (MSM) 
than the general population. While an estimated 40% of all HIV-
positive men are unaware of their HIV status, estimates among MSM 
are currently closer to 70%.[4,5] Current HTS coverage is insufficient 
among hard-to-reach groups, such as MSM and sex workers, who bear 
a disproportionate burden of HIV and experience barriers to accessing 
HIV testing in clinics. Research suggests that increased coverage of 
clinic-based HTSs is insufficient to encourage improved testing uptake 
and treatment initiation, and therefore does not reduce rates of HIV 
infection in high-risk groups.[6] 
It is critical that we expand HIV testing options for key populations 
with approaches that are responsive to their needs. HIV self-screening 
(HIVSS) has been found to be highly acceptable among MSM,[7-21] and 
may be effective in reducing the time to diagnosis and treatment and 
thus the incidence of new HIV infections.[9] MSM at our research site 
in Mpumalanga preferred HIVSS to clinic-based testing, with >80% 
stating a preference for the former.[7] Despite its potential, HIVSS has 
not been fully embraced by policymakers. This is partly due to lack of 
information regarding how best to deliver or distribute tests and how to 
financially structure the cost of distributing HIVSS nationally.[10] Fear 
of social harms, including psychological risk and potential coercion 
of stigmatised populations, has also delayed self-screening expansion. 
Policy regarding HIVSS and the legal framework to include it 
in national HTS efforts vary according to country.[11] High-income 
countries, such as the USA and UK, introduced over-the-counter 
(OTC) sales in early 2012 and 2014, respectively. France and Ireland 
subsequently implemented their HIVSS policies. Among African 
countries, Kenya was the first to develop its HTS national policy 
to include the oral fluid HIVSS kit in 2008.[12] In SA, before 2015, 
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unregulated sale of HIVSS kits in the absence of policy raised concerns 
of misuse of OTC sales by retail pharmacies and supermarkets.[13] In 
May 2015, the SA Pharmacy Council facilitated legalising the selling of 
HIVSS kits by adding them to the pharmacy register. This followed the 
lifting of a 1-year ban of the kits by the Pharmacy Council and marked 
a major milestone towards adopting HIVSS in SA. The Southern 
African HIV Clinicians Society developed a document on self-testing 
policy and guidance considerations.[14] This was followed by the 
publication of the National Department of Health HIVSS guidelines in 
May 2018,[22 ] which focus on considerations for effective and safe use of 
HIVSS. While potential distribution channels are listed (community-
based, facilities-based, secondary distribution to partners), detailed 
guidance for implementation (when, where and how to distribute tests) 
is not provided, given the lack of data across target groups needed to 
guide implementation. Key populations, with large unmet needs for 
accessible tests, should be prioritised regarding HIVSS roll-out, which 
requires targeted distribution. Although the healthcare system in SA 
can be accessed through local clinics, clinic-based testing is often 
impractical for MSM, who face barriers and stigma related to public 
health services owing to their sexual orientation. The SA government 
will possibly need to consider other distribution channels, such as 
community-based organisations (CBOs) and peer groups, which may 
be more readily accessible to key populations.[13]
The inclusion of HIVSS as part of the SA HTS policy could 
contribute to testing uptake and frequency, moving the country closer 
to its target of 90-90-90 by 2020.[15] To achieve these targets, gaps in 
programming for the needs of MSM must be addressed. We aimed 
to provide data directly applicable to inform policy, which would 
enable widespread distribution and use of HIVSS by MSM in SA, thus 
specifically addressing the current gaps in knowledge regarding where 
and how these test kits can be distributed, and identifying potential 
social benefits and harms linked to HIVSS. 
Methods
This study was conducted among MSM at two study sites in peri-
urban districts of Mpumalanga: Gert Sibande, semi-rural, but with a 
vibrant gay-identified community of MSM, whose networks span the 
rural towns of Msukaligwa (Ermelo), Makhado (Piet Retief), Secunda, 
Standerton and Volksrust; and Ehlanzeni district municipality, which 
contains the administrative capital Mbombela (Nelspruit) – a hub for 
tourists visiting the Kruger National Park. These two sites were home to 
the Mpumalanga Men’s Study (MPMS) (2012 - 2015),[3] a series of cross-
sectional seroprevalence surveys using respondent-driven sampling 
(RDS), as well as Project Boithato, an adapted Mpowerment Project 
focusing on MSM. Participants were randomly selected among those 
not known to be HIV-positive from the most recent MPMS RDS survey 
in Gert Sibande. In Ehlanzeni, participants were recruited from the most 
recent MPMS survey and, as more time had elapsed and fewer MPMS 
participants were reachable, participants were recruited with a new RDS.[7] 
Criteria for the RDS surveys included being ≥18 years of age and sexually 
active (oral or anal intercourse) with at least one other man in the past 
6 months. The recruitment, eligibility procedures and outcomes for 
MPMS and the main HIVSS study are described elsewhere.[3,7]
Data collection
Participants were invited to the study sites, which are located in both 
areas at the offices of a local non-governmental organisation known in 
the community for working with MSM. Participants provided written 
informed consent and, if interested in participating, were then tested 
for HIV by a trained test counsellor to ensure negative status prior to 
enrolment. Participants completed a behavioural questionnaire and 
were shown and provided instructions and a demonstration of use 
of blood (AtomoRapid HIV-½ Antibody Test, Atomo Diagnostics, 
Australia) and oral fluid-based (OraQuick ADVANCE Rapid HIV-½ 
Antibody Test, OraSure Technologies, USA) self-test kits. They were 
provided with up to 5 HIVSS kits – either blood or oral fluid based, 
depending on their choice – and asked to use these at least once before 
a subsequent visit after 3 months. Participants could share the tests 
with sexual partners or others with whom they felt comfortable. 
Participants returned for a follow-up visit 3 months after enrolment, 
when they responded to a questionnaire regarding use of the kits, 
preferences for use and social harms and benefits. They were offered 
an additional 4 HIVSS kits of their choice (either blood or oral fluid 
based, which could be different from their choice at baseline) and 
asked to return 6 months after enrolment for a final follow-up visit, 
which included a questionnaire with the acceptability/feasibility and 
social harms/benefits measures described above, as well as items 
regarding participants’ experiences with self-screening and preferences 
for distribution and pricing.
If participants were to obtain test kits in the future, they were 
asked where they would prefer to collect them. Response options 
included: CBOs, clinics, pharmacies or another distribution site. Only 
1 participant opted for something other than these responses, stating 
‘anywhere they are available’. Participants were asked how much 
they would be willing to pay for test kits in local SA currency – this 
was an open-ended rather than multiple-choice response. Response 
options were later grouped into: would not pay for HIVSS kits; would 
pay <ZAR24 (<USD2); or >ZAR25 but not >ZAR49; or >ZAR50 
(>USD4). Participants were also asked about social benefits and harms. 
One of the questions enquired if anything bad had happened as a 
result of participating in the study, and another if anything good had 
happened. These open-ended responses were qualitatively coded into 
one or more themes, including the primary good and bad outcomes 
for each participant. Participants requiring medical follow-up (testing 
positive or reporting other clinical needs) were referred to local MSM-
competent healthcare facilities.
Data analysis
Data analysed included responses to the behavioural questionnaires 
at baseline demographics, and to the acceptability and feasibility 
questionnaires at 3 and 6 months. Data were captured using the 
Question naire Development Software (QDS) (NOVA Research, USA) 
computer-assisted personal interview (CAPI) module, and exported 
to Stata 14 (StataCorp., USA). We generated basic frequency tables 
to describe the population characteristics. We also assessed HIVSS 
distribution preferences by demographic characteristics and used 
Fisher’s exact test to assess these differences. We report distribution of 
reported benefits and harms, and willingness to pay for HIVSS. 
Ethical approval
Ethical approval to conduct the study was obtained from the University 
of California, San Francisco Committee on Human Research (ref. nos 
iIRB14-13678 and 167347) and the University of the Witwatersrand 
Human Research Ethics Committee (ref. no. M140725). The US 
Centers for Disease Control and Prevention, one of the study sponsors, 
also approved the protocol, as well as the Mpumalanga Department of 
Health and Social Development Research Committee. 
Results 
Demographic characteristics
Of 127 eligible participants who consented to and enrolled in the 
study at baseline, 51 from Gert Sibande and 63 from Ehlanzeni 
(N=114) responded to questionnaire items regarding their experiences 
and preferences with an HIVSS kit at follow-up, including cost and 
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preference for collection, and are included in the analysis. They were 
notably young, with 65% <25 years of age, and only one-third employed 
in the past 6 months. Other demographic results are described 
elsewhere.[7] Table 1 includes preferences for HIVSS distribution by 
demo graphic characteristics.
Preference for distribution point was similar across demographic 
characteristics, with the exception of those with some college or technical 
education (92%), who preferred the CBO option to the clinic or 
pharmacy option (p<0.01). Younger men (18 - 24 years old), and those 
who did not identify as gay or bisexual, demonstrated some preference 
for distribution at community organisations (49.4%) and clinics (46.8%) 
rather than at a pharmacy (3.9%). Participants in Gert Sibande also 
favoured CBO distribution points (>60%). 
Social benefits and harms
At the 3-month visit, the majority of participants at both study sites 
– 97.9% in Gert Sibande and 94% in Ehlanzeni – reported only social 
benefits, or some ‘good thing’ that had happened to them as a result 
of being in the HIVSS study. At 6 months, 100% at both sites who 
returned for their follow-up visit reported benefits, and only 2.1% 
reported any harm. The responses largely mapped into 6 categories 
of benefits and 2 categories of harms. The most commonly reported 
benefit was knowledge gain of HIV and prevention, which was noted 
by ~30% of those in Gert Sibande at the 3- and 6-month visits and by 
>50% of the participants at 3 months (54%) and at 6 months (68%) 
in Ehlanzeni (Table 2). The benefit of knowledge of HIV status was 
also often reported at both sites by ~35% of participants at 3 months. 
Improved communication with partners was reported by 25% and 
44% of those in Gert Sibande at 3 and 6 months, respectively, although 
this was less common in Ehlanzeni – reaching 18.5% at 6 months. 
The most common secondary themes of benefits emerged as privacy, 
empowerment gained from testing oneself and other community 
benefits (e.g. educating family and friends about HIVSS kits). 
Reported harms were rare. At the Gert Sibande study site, 1 person 
reported experiencing social pressure to distribute kits due to high 
demand in the community. There were no social harms reported at 
the 6-month follow-up visits. Two participants in Ehlanzeni noted 
that receiving information relating to HIV-seropositive test results 
from friends, family or partners to whom they distributed kits, was a 
negative experience.
HIV self-screening kit pricing preference
Overall, 44 participants (38.6%) stated that they would not pay for 
an HIVSS test, given access to free testing at the clinic (Table 3). Less 
than one-quarter would pay <ZAR24 (<USD2) and <24% would 
pay ZAR25 - 49 (<USD4) if the kits were available for purchase or 
sold OTC. A small proportion (13.2%) of participants were willing 
to pay >ZAR50 (~USD4) for the HIVSS kits if these were available 
commercially. Willingness to pay did not differ substantively by age, 
sexual identity or testing history; those with tertiary education were a 
little less willing to pay for HIVSS than those with Matric (secondary 
school) only.
Table 1. Preference for HIV self-test distribution by demographic characteristics of the HIVSS MSM cohort
Preference for HIVSS distribution point (N=114)
Characteristics
Community organisation
(n=58, 50.9%), n (%)
Clinic 
(n=50, 43.9%), n (%)
Pharmacy 
(n=6, 5.3%), n (%)
Fisher’s exact
p-value
Age, years 0.21
18 - 24 37 (49.3) 32 (42.7) 6 (8.0)
25 - 39 21 (53.8) 18 (46.2) 0 (0.0)
Education <0.01
Primary or secondary 27 (49.1) 27 (49.1) 1 (1.8)
Matric (graduated high school) 19 (41.3) 23 (50.0) 4 (8.7)
Some college or technical school 12 (92.3) 0 (0.0) 1 (7.7)
Employment in past 6 months 0.23
Yes 21 (58.3) 12 (33.3) 3 (8.3)
No 37 (47.4) 38 (48.7) 3 (3.8)
Sexual identity 0.71
Gay/homosexual 17 (51.5) 13 (39.4) 3 (9.1)
Bisexual 38 (49.4) 36 (46.8) 3 (3.9)
Straight 2 (66.7) 1 (33.3) 0
Transgender 1 (100) 0 0
Sexual partners in past 6 months 0.53
0 2 (66.7) 1 (33.3) 0
1 38 (55.9) 36 (38.2) 4 (5.9)
≥2 18 (41.9) 23 (53.5) 2 (4.7)
Testing history prior to study, months 0.85
0 - 6 21 (45.7) 21 (45.7) 4 (8.7)
>6 - 12 17 (54.8) 12 (38.7) 2 (6.5)
>12 10 (52.6) 9 (47.4) 0
Never tested 10 (55.6) 8 (44.4) 0
Study site location 0.17
Gert Sibande 31 (60.8) 18 (35.3) 2 (3.9)
Ehlanzeni 27 (42.9) 32 (50.8) 4 (6.3)
HIVSS = HIVself-screening; MSM = men who have sex with men.
Note: table includes row percentages to assess different preferences by demographic group.
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Discussion
Our study demonstrates a clear preference among MSM in these 
two rural districts for distribution of HIVSS kits through CBOs 
that specialise in key population programming. It also shows that 
clinic-based distribution is feasible and acceptable to many MSM 
(or to MSM who are openly ‘out’ regarding their gay-identified 
sexual orientation) once the HIVSS kits become available. In the SA 
context, policymakers frequently support centralisation of services 
in major hospitals, clinics or pharmacies; our data suggest that 
centralised distribution through the public health service may 
hinder optimal uptake of HIVSS among MSM, who still face stigma 
and discrimination in accessing healthcare services, particularly 
in seeking HIV and other sexual healthcare.[8] Bisexual and other 
non-gay identified MSM, who are the most ‘hidden’ members of the 
MSM population, may fear having their sexual practices disclosed by 
presenting at clinics for HIV testing as MSM; it is critical to increase 
uptake of HIV testing among these men, who, as primarily insertive 
partners with men, may acquire and transmit HIV through either 
homosexual and heterosexual intercourse.[16] The preference for 
distribution through CBOs may allow HIVSS to be a complementary 
service while the organisations engage in peer-led outreach activities. 
Based on these research findings, key and hidden populations 
will possibly have improved access to and uptake of HIVSS kits if 
distributed through CBOs. 
Our research found no evidence of social harms related to HIVSS 
among MSM other than the increasing demand for kits in these 
communities and learning of the seropositive results of others to whom 
MSM had distributed kits. Instead, findings indicated that in this MSM 
community, exposure to HIVSS elicited the value placed on knowing 
one’s status and the eagerness of the community to test more frequently 
and acquire more knowledge. Empowerment was also cited as a social 
benefit resulting from HIVSS, emphasising the power of autonomy and 
taking pride and responsibility in regular testing. Finally, ~25% of MSM 
in our cohort reported the benefit of increased testing discussions and 
communication with partners, which signalled the potential for 
HIVSS to encourage disclosure discussions. Couple counselling and 
testing is uncommon, even among heterosexuals; it might even be 
less common among MSM who do not access clinic services.[17] Other 
studies have shown that among gay couples, an existing dynamic 
of support and communication around HIV influences sexual risk 
behaviour in relationships outside the primary relationship, leading to 
decreased risk of HIV transmission.[18] This open communication not 
only encourages regular HIV testing, but influences more informed 
choices regarding sexual practices among MSM. HIVSS provided an 
opportunity for regular testing and HIV support, which may involve 
disclosure if one should test HIV-positive.[19] In our study, testing with 
partners or friends had an empowering effect on MSM participants, 
not only regarding HIV support, but also by indicating the potential 
of uptake of HIV testing in the general population, where some 
participants distributed test kits to non-MSM family members.
Policymakers have had concerns regarding HIVSS possibly 
eliminating the role of pre- and post-test counselling, which has 
been the cornerstone of the SA HIV programme. Concerns about 
psychological distress among those who test in the absence of 
professional counselling were unfounded in this cohort. None of the 
114 participants mentioned lack of counselling as a problem. As there 
is a preference for the distribution of kits through CBOs, this provides 
a window of opportunity to train peer outreach workers, as well as 
Table 3. Willingness of MSM cohort to pay for an HIVSS kit at final study visit
HIVSS kit distribution
Overall
(N=114), n (%)
Gert Sibande
(n=51), n (%)
Ehlanzeni
(n=63), n (%)
How much would you pay for the HIVSS kit?
Would not pay 44 (38.6) 19 (37.3) 25 (39.7)
Would pay <ZAR24 (<USD2) 28 (24.6) 20 (39.2) 8 (12.7)
Would pay ZAR25 - 49 (<USD4) 27 (23.7) 10 (19.6) 17 (27.0)
Would pay ≥ZAR50 (≥USD4) 15 (13.2) 2 (3.9) 13 (20.6)
MSM = men who have sex with men; HIVSS = HIVself-screening.
Table 2. Reported social benefits and harms to participation in HIV self-screening
Gert Sibande Ehlanzeni
Benefits and harms*
3 months
(n=48), n (%)
6 months
(n=45), n (%)
3 months
(n=50), n (%)
6 months
(n=65), n (%)
Social benefits 
Knowledge gained regarding HIV/prevention 15 (31.3) 13 (28.9) 27 (54.0) 44 (67.7)
Knowing HIV status 17 (35.4) 11 (24.4) 18 (36.0) 12 (18.5)
Improved partner communication 12 (25.0) 20 (44.4) 3 (6.0) 12 (18.5)
Privacy 3 (6.3) 1 (2.2) 3 (6.0) -
Empowerment 8 (16.7) 3 (6.7) 6 (12.0) 11 (16.9)
Benefits to others/community 9 (18.8) 1 (2.2) 8 (16.0) -
Reported no benefit 1 (2.1) - 2 (4.0) 4 (6.2)
Social harms 
Pressure to distribute kits 1 (2.1) - - -
Testing positive and receiving results - - 2 (4.0) -
Reported no harms 47 (97.9) 45 (100.0) 47 (94.0)† 65 (100.0)
*Open text field response, coded qualitatively; some participants’ responses contained >1 theme.
†One participant did not respond to the questions on social harms and benefits. 
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other community-based counsellors. Thus, they can intervene in cases 
of harmful psychosocial effects and encourage confirmatory testing, 
where counselling is provided. 
We further note that our findings argue against the exclusive 
introduction of cost-based HIVSS, suggesting that it may lead to 
barriers in accessing the test kits in this semi-rural and largely low-
income community, as <15% were prepared to pay >ZAR50. With 
the recent agreement between OraSure Technologies and the Bill and 
Melinda Gates Foundation, which made the OraQuick HIVSS test 
available at a reduced price of USD2 in the public sector in 50 countries, 
including SA,[20] ~25% of our cohort participants would be able to 
afford the kits. 
Study limitations
We acknowledge the small sample size, which limits our ability to 
generalise findings to the entire MSM population of SA. Retention 
was high (89%); however, we are unable to report on the attitudes and 
perceptions of those who did not return, who may be less receptive to 
HIVSS. Self-reported outcomes are always subject to social desirability 
and recall bias. Our method did not allow us to directly observe MSM 
partner testing. Furthermore, some of the lingering questions in the 
field about linkage, which are important, fell outside of the feasibility/
acceptability scope of the study. Future studies are needed to explore 
some of these remaining questions.
Conclusion 
Despite the limitations of this small observational study, the 
overwhelming perception of the benefits of HIVSS was quite clear in 
the community, where increasing access to HIV testing is imperative. 
We found evidence that MSM would benefit from accessing HIVSS 
through non-governmental and/or CBOs working with key populations 
at no or low cost. There were many reported social benefits of HIVSS 
and negligible social harms. Much work still needs to be done to 
investigate best practices for linkage to care for those who test HIV-
positive using HIVSS; nonetheless, HIVSS has the potential to increase 
uptake of testing among hard-to-reach groups, thereby enhancing 
progress on reaching the first 90. In SA, to reach each of the 90-90-90 
targets, the focus should be on HIVSS, which may be the cornerstone 
of addressing major barriers to achieving these targets by 2030, thereby 
reaching those with the largest unmet need for alternatives to HTS.
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